Fresenius Medical Care AG & Co. (NYSE:FMS) has received a consensus recommendation of “Hold” from the eleven research firms that are currently covering the firm, Analyst Ratings Net reports. Six equities research analysts have rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year target price among brokers that have covered the stock in the last year is $41.10.

Fresenius Medical Care AG & Co. (NYSE:FMS) traded down 0.88% on Wednesday, hitting $41.56. 39,558 shares of the company traded hands. The stock has a market cap of $25.26 billion and a PE ratio of 24.04. The stock’s 50-day moving average is $42.54 and its 200 day moving average is $41.33. Fresenius Medical Care AG & Co. has a 12 month low of $32.40 and a 12 month high of $44.34.

Fresenius Medical Care AG & Co. (NYSE:FMS) last issued its quarterly earnings data on Thursday, July 30th. The company reported $0.40 earnings per share (EPS) for the quarter, missing the analysts’ consensus estimate of $0.42 by $0.02. During the same quarter in the prior year, the company posted $0.42 EPS. The business had revenue of $4.20 billion for the quarter, compared to the consensus estimate of $4.13 billion. Fresenius Medical Care AG & Co.’s revenue was up 15.0% compared to the same quarter last year. Equities research analysts expect that Fresenius Medical Care AG & Co. will post $1.76 earnings per share for the current fiscal year.

Several brokerages have recently weighed in on FMS. RBC Capital boosted their price objective on shares of Fresenius Medical Care AG & Co. from $35.00 to $40.00 and gave the stock a “sector perform” rating in a report on Friday, July 31st. Commerzbank AG cut shares of Fresenius Medical Care AG & Co. to a “hold” rating in a research report on Friday, May 29th.

Fresenius Medical Care AG & Co. KGaA (NYSE:FMS) is a kidney dialysis company. The Company provides dialysis care services related to the dialysis treatment a patient receives with end-stage renal disease (ESRD), as well as other health care services. FMC AG & CO. KGAA also provides dialysis products for the treatment of ESRD, which includes manufacturing and distributing products, such as hemodialysis machines, peritoneal cyclers, dialyzers, peritoneal solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals and systems for water treatment. The Company’s health care services, referred to as care coordination services, include pharmacy services, vascular, cardiovascular and endovascular specialty services, non-dialysis laboratory testing services, physician services, hospitalist and intensivist services, health plan services and urgent care services. The Company also offers a range of dialysis drugs.

Receive News & Ratings for Fresenius Medical Care AG & Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care AG & Co. and related companies with MarketBeat.com's FREE daily email newsletter.

...